Stockreport

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

Theriva Biologics, Inc.  (TOVX) 
PDF Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma [Read more]